Principal Scientist, Clinical Biomarker, Immunology, Immuno-Oncology, & Hematology (Contractor)

Principal Scientist, Clinical Biomarker, Immunology, Immuno-Oncology, & Hematology (Contractor) Employer Legend Biotech Location Somerset, New Jersey Start date Jun 2, 2026 View more categories View less categories Discipline Clinical , Science/R D , Bioengineering , Biotechnology Required Education Doctorate/PHD/MD Position Type Contract Apply now Save job Click to add the job to your shortlist You need to sign in or create an account to save a job. Send job Job Details Company Job Details Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking a Principal Scientist, Clinical Biomarker, Immunology, Immuno-Oncology, & Hematology (Contractor) as part of the Research & Development team based in Somerset, NJ. Role Overview We are seeking a highly motivated and innovative Principal Scientist to join our immunology and immuno-oncology (IO) clinical biomarker projects, with a dedicated focus on hematological malignancies. In this role, you will drive the clinical translational understanding of novel therapy in hematology. You will serve as the biology lead on cross-functional project teams, drive MOA of novel cell therapy and clinical biomarker strategy.

Contract Duration:

12 months

Key Responsibilities Scientific Leadership:

Design, execute, and analysis results from clinical studies to investigate the mechanisms of action for novel IO targets in hematological indications (e.g., AML, DLBCL, Multiple Myeloma).

Translational Strategy:

Bridge discovery and clinical development by utilizing primary human samples and clinical datasets to validate targets and understand the immune microenvironment in hematology.

Understanding MOA:

Oversee the generation and interpretation of high-dimensional molecular and cellular data. Leverage advanced single-cell technologies (e.g., scRNA-seq) to deeply profile immune cell compartments, particularly T-cell states and exhaustion markers, to inform patient stratification and biomarker hypotheses.

Cross-Functional Collaboration:

Partner closely with other functional teams for better understanding of MOA and fundamental immunology Requirements Ph.D. in Immunology, Immuno-Oncology, Cellular Biology, or a closely related discipline, can initiate and lead data driven MOA studies. Experience with cell therapy a plus but not required. A minimum of 5-8+ years of post-doctoral and/or industry experience in biotech or pharma, with a proven track record of advancing IO programs. Deep understanding of immunology, particularly T cell biology highly desirable. Deep biological understanding of hematological malignancies and the unique tumor immune microenvironment of the blood and bone marrow. Experience working with multiple dimensional data, extract biological insights from data highly desirable. Exceptional written and verbal communication skills, with the ability to distill complex data into clear, actionable strategic decisions. #Li-JR1 #Li-Contract Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech. EEO Statement It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances. Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company. For information related to our privacy notice, please review: Legend Biotech Privacy Notice . Company Legend Biotech was founded as an early-stage cell therapy company in 2014. The company was the brainchild of visionary scientists who recognized that antibody-based therapeutics could potentially treat disease and possessed the backgrounds in immunology and gene editing to take the leap. For two years, Legend Biotech, then known as the "Legend Project," operated in a room the size of a freight elevator, with the goal of creating a cell therapy for multiple myeloma, a hematological cancer that often relapses and can become refractory. The team produced nanobodies for single-domain antibody drugs and ultimately extended the half-life of the nanobodies with proprietary technologies. In 2015, Legend's scientists focused on research for chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein, making the biotech one of the first companies in the world to engineer CAR-T cells for the BCMA protein. In 2016, investigator-initiated trials began in China. In 2017, data from the trials were presented at the American Society for Clinical Oncology (ASCO), which led to a partnership with biopharmaceutical company Janssen Biotech, Inc. to co-develop the anti-BCMA CAR-T, ciltacabtagene autoleucel (cilta-cel). Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world.

CARVYKTI

™ (ciltacabtagene autoleucel) was approved by the U.S. Food and Drug Administration in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022. Today Legend Biotech is a global, commercial-stage company driven by a passion for patients. We continue to build our pipeline of cell therapy platforms, which includes CAR-T, CAR-NK, CAR-γδ T and non-gene-editing CAR technologies. Our goal is to bring hope and opportunity to patients and their families by continuing to explore unique technologies. Company info Location Somerset New Jersey United States Share this job Facebook Twitter LinkedIn Apply now Send job Apply now Save job Click to add the job to your shortlist You need to sign in or create an account to save a job. Get job alerts Create a job alert and receive personalized job recommendations straight to your inbox. Create alert